FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309213023> ?p ?o ?g. }

• W4309213023 endingPage "2459" @default.
• W4309213023 startingPage "2459" @default.
• W4309213023 abstract "Background: To determine medication adherence to intranasal corticosteroid spray (INCS) among allergic rhinitis (AR) patients with comorbid medical conditions. Methods: A cross-sectional study was conducted. Adults above 18 years old with persistent symptoms of AR and comorbid physician-diagnosed asthma, eczema, diabetes mellitus (DM) and hypertension (HPT) were included. The severity of symptoms was assessed by the total nasal symptom score (TNSS), medication adherence was based on the patients’ diaries and barriers to adherence were analyzed by the Brief Medication Questionnaire. Results: 185 participants were enrolled. The medication adherence was 58.9%. Medication adherence was significantly superior in participants with elevated total serum immunoglobulin E (IgE) (χ2 = 8.371, p < 0.05), house dust mite (HDM) allergy to Dermatophagoides pteronyssinus (DP) type (χ2 = 5.149, p < 0.05) and severe TNSS at the first visit (χ2 = 37.016, p < 0.05). Adherence was twice more likely in DP allergy, 2.7 times more likely in elevated total IgE and 15 times more likely in severe TNSS at the first visit. Among the barriers to adherence was lack of symptoms, taking medication only when necessary, fear of adverse effects, running out of medication, experiencing bothersome effects, ineffective response, forgetfulness and taking too many medications. Only lack of symptoms, taking medication when symptomatic, fear of adverse effects and running out of medication were significant. No significant association was found between asthma/eczema (χ2 = 0.418, p > 0.05), HPT/DM (χ2 = 0.759, p > 0.05) and multi-medicine use (χ2 = 1.027, p > 0.05) with medication adherence. Conclusions: Patients having AR with severe nasal symptoms at first presentation, who are sensitized to DP HDM and who have elevated total serum IgE levels have a higher adherence to INCS use. The use of multiple medicines had no impact on the adherence to INCS. As a lack of symptoms was a barrier towards adherence, the benefits of using INCS according to the prescribed dose and frequency must be emphasized to patients with mild and moderate AR at each medical visit. A good rapport between patients and their health care providers is needed to build trust and overcome the barriers, particularly to allay the fears of adverse effects of INCS. The other barriers, such as running out of supply, can be overcome by posting medications directly to patients by the healthcare providers." @default.
• W4309213023 created "2022-11-24" @default.
• W4309213023 creator A5005145032 @default.
• W4309213023 creator A5006139172 @default.
• W4309213023 creator A5027516867 @default.
• W4309213023 creator A5050618876 @default.
• W4309213023 creator A5070336887 @default.
• W4309213023 date "2022-11-15" @default.
• W4309213023 modified "2023-10-18" @default.
• W4309213023 title "Medication Adherence to Intranasal Corticosteroids in Allergic Rhinitis Patients with Comorbid Medical Conditions" @default.
• W4309213023 cites W1558845656 @default.
• W4309213023 cites W1741567663 @default.
• W4309213023 cites W2000805694 @default.
• W4309213023 cites W2018086889 @default.
• W4309213023 cites W2035636901 @default.
• W4309213023 cites W2048643749 @default.
• W4309213023 cites W2059576911 @default.
• W4309213023 cites W2062100572 @default.
• W4309213023 cites W2067054269 @default.
• W4309213023 cites W2068483366 @default.
• W4309213023 cites W2077241603 @default.
• W4309213023 cites W2081238165 @default.
• W4309213023 cites W2114846821 @default.
• W4309213023 cites W2140144472 @default.
• W4309213023 cites W2474131267 @default.
• W4309213023 cites W2552918548 @default.
• W4309213023 cites W2804479695 @default.
• W4309213023 cites W2883642765 @default.
• W4309213023 cites W2890229003 @default.
• W4309213023 cites W2905161911 @default.
• W4309213023 cites W2916610774 @default.
• W4309213023 cites W2954558027 @default.
• W4309213023 cites W2985655914 @default.
• W4309213023 cites W2990199768 @default.
• W4309213023 cites W2993910655 @default.
• W4309213023 cites W3011703392 @default.
• W4309213023 cites W3124369735 @default.
• W4309213023 cites W3127775810 @default.
• W4309213023 cites W3173571816 @default.
• W4309213023 cites W3184262661 @default.
• W4309213023 doi "https://doi.org/10.3390/pharmaceutics14112459" @default.
• W4309213023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36432649" @default.
• W4309213023 hasPublicationYear "2022" @default.
• W4309213023 type Work @default.
• W4309213023 citedByCount "4" @default.
• W4309213023 countsByYear W43092130232023 @default.
• W4309213023 crossrefType "journal-article" @default.
• W4309213023 hasAuthorship W4309213023A5005145032 @default.
• W4309213023 hasAuthorship W4309213023A5006139172 @default.
• W4309213023 hasAuthorship W4309213023A5027516867 @default.
• W4309213023 hasAuthorship W4309213023A5050618876 @default.
• W4309213023 hasAuthorship W4309213023A5070336887 @default.
• W4309213023 hasBestOaLocation W43092130231 @default.
• W4309213023 hasConcept C126322002 @default.
• W4309213023 hasConcept C134018914 @default.
• W4309213023 hasConcept C141105273 @default.
• W4309213023 hasConcept C159654299 @default.
• W4309213023 hasConcept C197934379 @default.
• W4309213023 hasConcept C203014093 @default.
• W4309213023 hasConcept C207480886 @default.
• W4309213023 hasConcept C2776042228 @default.
• W4309213023 hasConcept C2776804153 @default.
• W4309213023 hasConcept C2778166374 @default.
• W4309213023 hasConcept C2780510475 @default.
• W4309213023 hasConcept C3018553135 @default.
• W4309213023 hasConcept C3018952834 @default.
• W4309213023 hasConcept C555293320 @default.
• W4309213023 hasConcept C71924100 @default.
• W4309213023 hasConcept C85663871 @default.
• W4309213023 hasConceptScore W4309213023C126322002 @default.
• W4309213023 hasConceptScore W4309213023C134018914 @default.
• W4309213023 hasConceptScore W4309213023C141105273 @default.
• W4309213023 hasConceptScore W4309213023C159654299 @default.
• W4309213023 hasConceptScore W4309213023C197934379 @default.
• W4309213023 hasConceptScore W4309213023C203014093 @default.
• W4309213023 hasConceptScore W4309213023C207480886 @default.
• W4309213023 hasConceptScore W4309213023C2776042228 @default.
• W4309213023 hasConceptScore W4309213023C2776804153 @default.
• W4309213023 hasConceptScore W4309213023C2778166374 @default.
• W4309213023 hasConceptScore W4309213023C2780510475 @default.
• W4309213023 hasConceptScore W4309213023C3018553135 @default.
• W4309213023 hasConceptScore W4309213023C3018952834 @default.
• W4309213023 hasConceptScore W4309213023C555293320 @default.
• W4309213023 hasConceptScore W4309213023C71924100 @default.
• W4309213023 hasConceptScore W4309213023C85663871 @default.
• W4309213023 hasIssue "11" @default.
• W4309213023 hasLocation W43092130231 @default.
• W4309213023 hasLocation W43092130232 @default.
• W4309213023 hasLocation W43092130233 @default.
• W4309213023 hasOpenAccess W4309213023 @default.
• W4309213023 hasPrimaryLocation W43092130231 @default.
• W4309213023 hasRelatedWork W1990054401 @default.
• W4309213023 hasRelatedWork W1991336296 @default.
• W4309213023 hasRelatedWork W2091524630 @default.
• W4309213023 hasRelatedWork W2125880895 @default.
• W4309213023 hasRelatedWork W2162200176 @default.
• W4309213023 hasRelatedWork W2312975841 @default.
• W4309213023 hasRelatedWork W2767618387 @default.

• next